This is the most likely risk factor for PCP development in this cohort, along with CD4+ lymphopenia, which has been observed in the majority of patients affected by COVID-19 and is associated with a poor prognosis, particularly in younger patients [37,38]. This evidence concerns the gene CD4 and COVID-19.